









市场行情
/
股票
/
nasdaq-crbu
/

Caribou Biosciences Inc

CRBU

1.720USD

+0.040+2.38%

收盘 12/22, 16:00（美东）报价延迟15分钟

160.77M总市值

亏损市盈率 TTM



Caribou Biosciences Inc

1.720

+0.040+2.38%

概览公司财务分析

概览

公司

财务

分析

关于 Caribou Biosciences Inc 公司

Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.

Caribou Biosciences Inc简介



公司代码CRBU

公司名称Caribou Biosciences Inc

上市日期Jul 23, 2021

CEOHaurwitz (Rachel E)

员工数量147

证券类型Ordinary Share

年结日Jul 23

公司地址2929 7Th Street, Ste 120

城市BERKELEY

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编94710

电话15109826030

网址https://www.cariboubio.com/

公司代码CRBU

上市日期Jul 23, 2021

CEOHaurwitz (Rachel E)

Caribou Biosciences Inc公司高管



名称

名称/职务

职务

持股

持股变动

Ms. Barbara G. McClung, J.D.

Chief Legal Officer, Corporate Secretary

381.25K

-7.13%

Mr. Sriram (Sri) Ryali

Chief Financial Officer

17.36K

Ms. Ruhi A. Khan

Chief Business Officer

Dr. Nancy C. Whiting, Pharm.D.

Independent Director

Mr. David Louis Johnson

Independent Director

Dr. Dara Richardson-Heron, M.D.

Independent Director

Dr. Tina Albertson, M.D., Ph.D.

Chief Medical Officer

Dr. Natalie R. Sacks, M.D.

Independent Director

Mr. Andrew L. Guggenhime

Independent Chairman of the Board

Dr. Scott N. Braunstein, M.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Ms. Barbara G. McClung, J.D.

Chief Legal Officer, Corporate Secretary

381.25K

-7.13%

Mr. Sriram (Sri) Ryali

Chief Financial Officer

17.36K

Ms. Ruhi A. Khan

Chief Business Officer

Dr. Nancy C. Whiting, Pharm.D.

Independent Director

Mr. David Louis Johnson

Independent Director

Dr. Dara Richardson-Heron, M.D.

Independent Director

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United States

1.66M

62.32%

Rest of world

1.00M

37.68%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月18日周二

持股股东

股东类型

持股股东

占比

Pfizer Inc

5.02%

The Vanguard Group, Inc.

4.52%

Haurwitz (Rachel E. Ph.D.)

3.68%

Millennium Management LLC

3.44%

Kynam Capital Management LP

3.28%

其他

80.06%

持股股东

占比

Pfizer Inc

5.02%

The Vanguard Group, Inc.

4.52%

Haurwitz (Rachel E. Ph.D.)

3.68%

Millennium Management LLC

3.44%

Kynam Capital Management LP

3.28%

其他

80.06%

股东类型

持股股东

占比

Investment Advisor

16.28%

Hedge Fund

13.43%

Investment Advisor/Hedge Fund

5.55%

Corporation

5.02%

Individual Investor

4.72%

Research Firm

2.40%

Private Equity

0.83%

Venture Capital

0.47%

Bank and Trust

0.05%

其他

51.25%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

336

36.52M

71.18%

+8.50K

2025Q3

343

36.51M

75.34%

-3.42M

2025Q2

344

39.93M

84.21%

-9.67M

2025Q1

343

49.60M

89.75%

-33.86M

2024Q4

341

57.02M

91.20%

-746.04K

2024Q3

336

56.25M

89.23%

-1.72M

2024Q2

332

57.28M

88.69%

-12.92M

2024Q1

319

69.74M

90.55%

-12.04M

2023Q4

311

71.96M

89.62%

-1.70M

2023Q3

307

73.59M

61.71%

+24.32M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Pfizer Inc

4.69M

5.04%

Jun 30, 2025

The Vanguard Group, Inc.

4.09M

4.39%

-432.17K

-9.56%

Jun 30, 2025

Haurwitz (Rachel E. Ph.D.)

3.44M

3.69%

-87.08K

-2.47%

Apr 22, 2025

Millennium Management LLC

1.55M

1.67%

+729.54K

+88.85%

Jun 30, 2025

Kynam Capital Management LP

3.07M

3.29%

-201.37K

-6.16%

Jun 30, 2025

Two Sigma Investments, LP

2.38M

2.55%

-112.17K

-4.51%

Jun 30, 2025

ACATIS Investment Kapitalverwaltungsgesellschaft GmbH

2.00M

2.15%

Jun 30, 2025

SELECTRA Management Company S.A.

1.50M

1.61%

-14.10K

-0.93%

Jul 31, 2025

BlackRock Institutional Trust Company, N.A.

1.83M

1.97%

-3.91M

-68.09%

Jun 30, 2025

abrdn Inc.

897.58K

0.96%

+486.44K

+118.31%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

AXS Green Alpha ETF

1.24%

WisdomTree BioRevolution Fund

0.52%

Avantis US Small Cap Equity ETF

0.01%

Schwab U.S. Small-Cap ETF

0.01%

DFA Dimensional US Core Equity Market ETF

Global X Genomics & Biotechnology ETF

ProShares Ultra Nasdaq Biotechnology

ProShares Hedge Replication ETF

Pacer WealthShield ETF

ProShares UltraPro Russell2000

AXS Green Alpha ETF

占比1.24%

WisdomTree BioRevolution Fund

占比0.52%

Avantis US Small Cap Equity ETF

占比0.01%

Schwab U.S. Small-Cap ETF

占比0.01%

DFA Dimensional US Core Equity Market ETF

占比0%

Global X Genomics & Biotechnology ETF

占比0%

ProShares Ultra Nasdaq Biotechnology

占比0%

ProShares Hedge Replication ETF

占比0%

Pacer WealthShield ETF

占比0%

ProShares UltraPro Russell2000

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Caribou Biosciences Inc的前五大股东是谁？



Caribou Biosciences Inc 的前五大股东如下：
Pfizer Inc持有股份：4.69M，占总股份比例：5.04%。
The Vanguard Group, Inc.持有股份：4.09M，占总股份比例：4.39%。
Haurwitz (Rachel E. Ph.D.)持有股份：3.44M，占总股份比例：3.69%。
Millennium Management LLC持有股份：1.55M，占总股份比例：1.67%。
Kynam Capital Management LP持有股份：3.07M，占总股份比例：3.29%。